Long-term consumption of non-fermented and fermented dairy products and risk of breast cancer by estrogen receptor status – Population-based prospective cohort study

Abstract Background The effect of dairy products intake on breast cancer (BC) is highly controversial. This study aims to investigate the relationship between dairy intake and BC incidence. Methods A search was carried out in PubMed, EBSCO, Web of Science, and Cochrane Library databases before January 2021. The primary objective was the risk of BC and intake of dairy products were exposure variables. Results The meta-analysis comprised 36 articles with 1,019,232 participants. Total dairy products have a protective effect on female population (hazard ratio (HR) =0.95, 95% confidence interval (CI) =0.91–0.99, p = 0.019), especially for estrogen receptor-positive (ER+) (HR = 0.79, p = 0.002) and progesterone receptor-positive (PR+) BC (HR = 0.75, p = 0.027). For ER+/PR+ BC, there is a trend of protection, but it has not reached statistical significance (HR = 0.92, p = 0.075). Fermented dairy products can reduce BC risk in postmenopausal population (HR = 0.96, 95%CI = 0.93–0.99, p = 0.021), but have no protective effect on premenopausal population (HR = 0.98, 95%CI = 0.94–1.03, p = 0.52). Non-fermented dairy products have no significant effect on BC occurrence (p > 0.05). High-fat dairy products are harmful to women, without statistical difference (HR = 1.06, 95%CI = 1.00–1.13, p = 0.066). On the contrary, low-fat dairy products can protect the premenopausal population (HR = 0.94, 95%CI = 0.89–1.00, p = 0.048). Conclusion The intake of dairy products can overall reduce BC risk in the female population, but different dairy products have varying effects on different BC subtypes and menopausal status.

Download Full-text

Activities and sources of income after a period of long-term sick leave - a population-based prospective cohort study

BMC Public Health ◽

10.1186/1471-2458-12-745 ◽

2012 ◽

Vol 12 (1) ◽

Cited By ~ 15

Author(s):

Anders Wikman ◽

Michael Wiberg ◽

Staffan Marklund ◽

Kristina Alexanderson

Keyword(s):

Cohort Study ◽

Sick Leave ◽

Prospective Cohort Study ◽

Prospective Cohort ◽

Population Based

Download Full-text

Abstract B22: Fatigue among long-term survivors of breast cancer: A prospective cohort study with longitudinal follow-up

10.1158/1940-6207.prev-11-b22 ◽

2011 ◽

Author(s):

Wendy Y. Chen ◽

Michelle D. Holmes ◽

Susan E. Hankinson

Keyword(s):

Breast Cancer ◽

Cohort Study ◽

Prospective Cohort Study ◽

Prospective Cohort ◽

Long Term Survivors

Download Full-text

Body mass index and breast cancer: analysis of a nation-wide population-based prospective cohort study on 1 393 985 Taiwanese women

International Journal of Obesity ◽

10.1038/ijo.2015.205 ◽

2015 ◽

Vol 40 (3) ◽

pp. 524-530 ◽

Cited By ~ 19

Author(s):

M-J Chen ◽

W Y-Y Wu ◽

A M-F Yen ◽

J C-Y Fann ◽

S L-S Chen ◽

...

Keyword(s):

Breast Cancer ◽

Body Mass Index ◽

Cohort Study ◽

Body Mass ◽

Prospective Cohort Study ◽

Prospective Cohort ◽

Population Based ◽

Taiwanese Women ◽

Wide Population

Download Full-text

Use of real-world data to study health services utilisation and comorbidities in long-term breast cancer survivors (the SURBCAN study): study protocol for a longitudinal population-based cohort study

BMJ Open ◽

10.1136/bmjopen-2020-040253 ◽

2020 ◽

Vol 10 (9) ◽

pp. e040253

Author(s):

Anna Jansana ◽

Isabel Del Cura ◽

Alexandra Prados-Torres ◽

Teresa Sanz Cuesta ◽

Beatriz Poblador-Plou ◽

...

Keyword(s):

Breast Cancer ◽

Cohort Study ◽

Health Services ◽

Cancer Survivors ◽

Real World ◽

Breast Cancer Survivors ◽

Population Based ◽

Real World Data ◽

World Data

IntroductionBreast cancer has become a chronic disease due to survival improvement and the need to monitor the side effects of treatment and the disease itself. The aim of the SURBCAN study is to describe comorbidity, healthcare services use and adherence to preventive recommendations in long-term breast cancer survivors and to compare them with those in women without this diagnosis in order to improve and adapt the care response to this group of survivors.Methods and analysisPopulation-based retrospective cohort study using real-world data from cancer registries and linked electronic medical records in five Spanish regions. Long-term breast cancer survivors diagnosed between 2000 and 2006 will be identified and matched by age and administrative health area with women without this diagnosis. Sociodemographic and clinical variables including comorbidities and variables on the use of health services between 2012 and 2016 will be obtained from databases in primary and hospital care. Health services use will be assessed through the annual number of visits to primary care professionals and to specialists and through annual imaging and laboratory tests. Factors associated with healthcare utilisation and comorbidities will be analysed using multilevel logistic regression models. Recruitment started in December 2018.Ethics and disseminationThis study was approved by the Ethics Committee of Parc de Salut Mar. The results of the study will be published in a peer-reviewed journal and will be presented at national and international scientific conferences and at patient associations.Trial registration numberThis protocol is registered in Clinical Trials.gov (identifier: NCT03846999).

Download Full-text

UNICANCER: Prospective cohort study of treatment related chronic toxicities in patients with localized breast cancer (CANTO).

Journal of Clinical Oncology ◽

10.1200/jco.2017.35.15_suppl.tps10125 ◽

2017 ◽

Vol 35 (15_suppl) ◽

pp. TPS10125-TPS10125

Author(s):

Ines Maria Vaz Duarte Luis ◽

Paul H. Cottu ◽

Christel Mesleard ◽

Anne-Laure Martin ◽

Agnes Dumas ◽

...

Keyword(s):

Breast Cancer ◽

Cohort Study ◽

Cancer Patients ◽

Prospective Cohort Study ◽

Prospective Cohort ◽

Treatment Completion ◽

Breast Cancer Patients ◽

European Organization ◽

Patient Reported

TPS10125 Background: Corresponding with improved survival among breast cancer patients an awareness of the long term effects of cancer treatments has increased. There is now a call for better coordination of care and management of these patients to focus on their survivorship. This study will identify factors associated with the development and persistence of long term toxicities in patients treated for Stage I-III breast cancer. In addition, it will characterize their incidence as well as, psychological, social and economic impacts. Methods: This is a prospective cohort study enrolling newly diagnosed invasive cT0-cT3, cN0-3, M0 breast cancer patients of 26 French comprehensive cancer centers. All patients will be followed for a minimum of 5 years. Patients will be assessed at diagnosis, 3-6 (M0), 12 (M12), 36 (M36), 48 (M48), 60 (M60), months after treatment completion. Treatment completion is defined as completion of primary surgery, chemotherapy or radiotherapy, whichever comes last. Adjuvant trastuzumab, endocrine therapy or participation in clinical trials can be ongoing. CANTO collects an extensive list of clinical, treatment, and toxicity data including validated patient reported outcomes questionnaires ( Hospital Anxiety and Depression scale [HADS], Scheier et Carver’s Questionnaire, Life Orientation Test-Revised [LOT-R], Beck Depression Inventory [BDI-SF], European Organization for Research and Treatment-QOL questionnaire for breast cancer [EORTC QLQC30-BR23], EORTC-FA13, 12 Item Short Form Survey [SF12], Global physical activity questionnaire [GPAQ]6, impact of cancer questionnaire [IOCv2], economic and social questionnaires). Blood collection is available for all patients at diagnosis, M0, M12, M36 and M60. Genotyping will be performed in all samples. Biologic substudies are ongoing (e.g, microbiotic and cognitive substudy). CANTO aggregates a multidisciplinary team of French investigators and created a dedicated national network. Enrolment started in 2012 and by December 2016, 10030 patients were already enrolled, with a goal of 12.000 patients. Clinical trial information: NCT01993498.

Download Full-text